Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
OTC
Return to: PBR Home | Production & Manufacturing | OTC

GlaxoSmithKline launches Eno digestive antacid in tablet, liquid forms

PBR Staff Writer Published 04 July 2013

UK-based GlaxoSmithKline's consumer healthcare unit has launched its Eno brand in chewy tablet and liquid forms to expand offering in digestive antacid market in India.

Used to cure acidity and other gastric issues, Eno was earlier available only in powder form.

With the transition into tablet, liquid forms, Eno will now compete with brands such as Abott's Digene, Pfizer's Gelusil and Piramal's Polycrol Gel. The competitor brands are sold as tablets and syrups.

The antacid market in India is divided into powder, tablet and liquid segments.

GlaxoSmithKline Consumer Healthcare executive vice president Jayant Singh was quoted by Press Trust of India as saying, "The liquid and tablet formats represent 55 per cent of the total digestive antacid market (in India) and we were not there. So, it was the obvious choice to enter these formats."

The launch is part of GlaxoSmithKline Consumer's increasing focus on its health and wellness portfolio, including brands such as Iodex, a pain reliever, and Crocin, a paracetamol and pain-reliever.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.